Opioid-Induced Constipation Management

Introduction to PAMORAs

Peripherally acting μ-opioid receptor antagonists (PAMORAs) are the most effective medications for treating opioid-induced constipation, with subcutaneous methylnaltrexone showing the highest efficacy among available options, according to the American Society of Clinical Oncology 1

The National Comprehensive Cancer Network recommends prophylactic treatment with stimulant laxatives (e.g., senna) with or without stool softeners should be started when initiating opioid therapy, and the laxative dose should be increased when increasing opioid dose, while maintaining adequate fluid intake and dietary fiber, and encouraging physical activity when feasible 2, 3

Methylnaltrexone is available in both subcutaneous injection and oral tablet forms, and is FDA approved for OIC in both advanced illness/palliative care and chronic non-cancer pain, with predictable effectiveness and a unique advantage of not being metabolized via CYP3A4, reducing drug-drug interactions, according to the American Gastroenterological Association 1, 4
Naloxegol is an oral once-daily PAMORA that improves spontaneous bowel movement (SBM) response and frequency with moderate-quality evidence, according to the American Gastroenterological Association 5
Naldemedine is an oral once-daily PAMORA with high-quality evidence supporting efficacy, and is effective in both cancer and non-cancer pain populations, according to the American Gastroenterological Association 6

PAMORAs should not be used in patients with known or suspected mechanical bowel obstruction, according to the National Comprehensive Cancer Network 3
Patients with inadequate response to laxatives show improved response rates with PAMORAs, according to the American Gastroenterological Association 7
Pain scores and mean daily opioid doses typically remain stable with PAMORA use, indicating they don't interfere with pain control, according to the American Gastroenterological Association 4

The National Comprehensive Cancer Network recommends starting stimulant laxative (senna) with stool softener (docusate) prophylactically when initiating opioids, and titrating laxative dose with goal of one non-forced bowel movement every 1-2 days 2
If constipation persists, rule out bowel obstruction and other causes, add osmotic laxatives, and consider adding bisacodyl, according to the National Comprehensive Cancer Network 3
For refractory OIC, initiate a PAMORA, with subcutaneous methylnaltrexone being the most effective option, according to the American Society of Clinical Oncology 1

Don't rely on fiber supplements like psyllium, which are ineffective and may worsen constipation, according to the National Comprehensive Cancer Network 8
Don't use docusate alone as it has not shown benefit, according to the National Comprehensive Cancer Network 8
Don't delay initiating PAMORAs when standard laxatives fail, according to the National Comprehensive Cancer Network 3
Don't use PAMORAs in patients with mechanical bowel obstruction, according to the National Comprehensive Cancer Network 3
Don't forget to maintain adequate fluid intake alongside laxative therapy, according to the National Comprehensive Cancer Network 2

The American Gastroenterological Association recommends naldemedine (0.2 mg once daily) as the strongest alternative to Relistor for adult patients with chronic non-cancer pain experiencing opioid-induced constipation, backed by high-quality evidence 9
Naloxegol (12.5-25 mg once daily) is a strong second choice, supported by moderate-quality evidence, and improves spontaneous bowel movement response and frequency 9
The FDA approves naldemedine and naloxegol for opioid-induced constipation in adults with chronic non-cancer pain 10

Lubiprostone (24 mcg twice daily) works through a different mechanism, activating chloride channels to enhance intestinal fluid secretion, and is FDA-approved for opioid-induced constipation in adults with chronic non-cancer pain 11
Subcutaneous methylnaltrexone demonstrates superior efficacy compared to oral formulations in network meta-analyses, but is reserved for patients who cannot tolerate oral medications or need maximum efficacy 9

The American College of Gastroenterology suggests initiating a PAMORA if patient has failed standard laxatives, with naldemedine preferred for highest quality evidence and once-daily oral dosing 10
Methylnaltrexone has a unique advantage of not being metabolized via CYP3A4, reducing potential drug interactions, while naloxegol and naldemedine require dose adjustments with strong CYP3A4 inhibitors 9
Absolute contraindications for all PAMORAs include mechanical bowel obstruction, and treatment should be monitored for response within 2 weeks using Bowel Function Index (target score <30) 11, 10

Verify abdominal radiograph (KUB) findings; a modest stool burden on imaging suggests functional constipation rather than a complete mechanical obstruction, warranting further medical therapy 12.
Perform a digital examination of the stoma (and any remaining rectal segment) to identify fecal impaction, which must be cleared before systemic agents are introduced 12.

Maximize stimulant laxatives (e.g., senna or bisacodyl 10–15 mg, administered 2–3 times daily) as they are the preferred first‑line agents for opioid‑induced constipation 12.
Add an osmotic laxative if not already in use—options include polyethylene glycol (~17 g daily), lactulose, or magnesium hydroxide—to enhance stool water content 12.
Avoid magnesium‑based laxatives in patients with renal impairment because of the risk of hypermagnesemia 12.
Do not incorporate bulk‑forming agents such as psyllium; evidence indicates they provide no benefit and may aggravate opioid‑induced constipation 12.

Ensure adequate fluid intake; proper hydration is essential for colostomy function and for the effectiveness of laxatives 12.
Recognize that positioning and timing of bowel movements are irrelevant in the presence of a colostomy; pharmacologic management should be the primary focus 12.
Enemas and suppositories may be unsuitable depending on the colostomy configuration; however, if a rectal segment remains, rectal bisacodyl can be considered 12.